HAE vs PCVX
Haemonetics vs Vaxcyte, Inc. — AI-powered side-by-side comparison
VS
PCVX
Vaxcyte, Inc.
64
Buy
| Metric | HAE | PCVX |
|---|
| AI Score |
49
|
64
|
| Price |
$108.42
|
$61.83
|
| P/E Ratio |
52.82×
|
-8.20×
|
| ROE |
12.2%
|
-28.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
57.4%
|
0.0%
|
| Debt / Equity |
1.40×
|
0.04×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.2
|
65.9
|
| Beta |
0.518
|
1.21
|
| Expected Upside |
+30.2%
|
+0.9%
|
AI Committee View
Current Innellis committee reasoning for HAE versus PCVX.
PCVX leads by 15 points.
PCVX scores 64/100 (Buy) versus HAE at 49/100 (Watch).
HAE Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — high leverage (debt-to-equity 1.54) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 43.2 is expensive by classic value standards — Value
- Debt-to-equity of 1.54 adds balance-sheet risk to the value case — Value
- EPS declining -37.4% YoY despite any revenue growth — Growth
PCVX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -37.6% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 20.8% signals elevated volatility — Risk